NCT00317499View on ClinicalTrials.gov

Double-blind, Randomized, Placebo-controlled Phase 3 Study of Etanercept in the Treatment of Psoriatic Arthritis and Psoriasis

PHASE3CompletedINTERVENTIONAL
Enrollment

205

Participants

Timeline

Start Date

April 30, 2000

Primary Completion Date

June 30, 2002

Study Completion Date

July 31, 2002

Conditions
Psoriatic ArthritisPsoriasis
Interventions
OTHER

Placebo

Placebo

DRUG

Etanercept

Etanercept

Sponsors

Lead Sponsor

Amgen

Collaborators (1)

Immunex Corporation
All Listed Sponsors
collaborator

Immunex Corporation

INDUSTRY

lead

Amgen

INDUSTRY

NCT00317499 - Double-blind, Randomized, Placebo-controlled Phase 3 Study of Etanercept in the Treatment of Psoriatic Arthritis and Psoriasis | Biotech Hunter | Biotech Hunter